Lineage Cell Therapeutics earns patent for stem cell-derived spinal cord injury treatment

Alan Condon -   Print  |
Listen

The U.S. Patent and Trademark Office issued a patent for Lineage Cell Therapeutics' stem cell-derived treatment for spinal cord injury.

Five things to know:

1. The patent is titled "pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury."

2. It covers processes that involve injecting OPCs obtained from a pluripotent human stem cell line into the spinal cord injury site and covers human embryonic and induced pluripotent stem cell-derived OPCs.

3. OPC1 cells are created by directing the developmental lineage of pluripotent cell lines to produce a consistent population of oligodendritic cells, which aim to provide post-injury regeneration for patients.

4. OPC1 is being tested in a Phase I/IIa clinical trial for the treatment of acute spinal cord injuries.

5. The patent expires in 2036.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers